200
Participants
Start Date
September 1, 2022
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
Terelizumab (aka Tislelizumab)
q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
CapeOx
Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
Trastuzumab
q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
Radiotherapy
25 Gy/5 fractions
RECRUITING
Army Medical Center, Chongqing
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
OTHER